Drug-related problems in type 2 diabetes mellitus patients with dyslipidemia

BMC Public Health

Lee Chai Ling¹  Hasniza Zaman Huri² 

[1] Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia;Clinical Investigation Centre, University Malaya Medical Centre, 13th Floor Main Tower, Lembah Pantai, Kuala Lumpur 59100, Malaysia

关键词: Dyslipidemia;    Drug-related problems;    Type 2 diabetes mellitus;   

Others  :  1161432
DOI  :  10.1186/1471-2458-13-1192

 received in 2013-08-05, accepted in 2013-12-12,  发布年份 2013

【 摘 要 】

Background

Drug-Related Problems (DRPs) commonly occur among type 2 diabetes mellitus (T2DM) patients. However, few studies have been performed on T2DM patients with dyslipidemia. This purpose of this study was to assess drug-related problems (DRPs) and factors associated with its occurrence.

Methods

The retrospective study involved 208 T2DM in-patients and out-patients with dyslipidemia, and was conducted at a tertiary hospital in Malaysia from January 2009 to December 2011. The identification and assessment of DRPs were based on the Pharmaceutical Care Network Europe (PCNE) tool version 5.01. The potentially inappropriate medication use in older adults was assessed based on the American Geriatrics Society updated Beers Criteria.

Results

A total of 406 DRPs were identified. Among these patients, 91.8% had at least one DRP, averaging 1.94 ± 1.10 problems per patient. The majority of T2DM patients with dyslipidemia (91.8%) had at least one DRP. The most frequent types of DRP were potential drug-drug interaction (18.0%), drug not taken or administered (14.3%) and insufficient awareness of health and diseases (11.8%). Anti-hypertensive, lipid-modifying and anti-diabetic agents were the drug classes that were most likely to be associated with DRPs. Male gender, renal impairment, polypharmacy and poor lipid control were factors that were significantly associated with DRP in diabetic dyslipidemia patients.

Conclusion

Early identification of DRPs and factors associated with them are essential to prevent and resolve DRPs in T2DM patients with dyslipidemia.

【 授权许可】

   
2013 Zaman Huri and Chai Ling; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]American Diabetes Association: Standard of medical care in diabetes. Diabetes Care 2012, 35(1):S11-S63.
• [2]Fagot CA, Rolka DB, Beckles GL, Gregg EW, Narayan KM: Prevalence of lipid abnormalities, awareness, and treatment in U.S. adults with diabetes. Abstract 318. Diabetes 2000, 49(Supplement 1):A78-A79.
• [3]Mooradian SD: Dyslipidemia in type 2 diabetes mellitus. Nature Clin Pract: Endocrinol Metab 2009, 5(3):150-159.
• [4]Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS 23). BMJ 1998, 316:823-828.
• [5]Pharmaceutical Care Network Europe Foundation: 2006, PCNE classification for drug-related problems version 5.01. 2006. Retrieved October 22, 2011, from http://www.pcne.org/sig/drp/documents/PCNE%20classification%20V5.01.pdf webcite
• [6]Haugbolle LS, Sorensen EW: Drug-related problems in patients with angina pectoris, type 2 diabetes and asthma: Interviewing patients at home. Pharm World Sci 2006, 28:239-247.
• [7]Bob W, Ines K: Development of an evidence-based checklist for the detection of drug-related problems in type 2 diabetes mellitus. Pharm World Sci 2009, 31:580-595.
• [8]Keith GT, Anthony D, Vivian F, Tan MH: Spectrum of liver disease in type 2 diabetes and the management of patients with diabetes and liver disease. Diabetes Care 2007, 30(3):734-743.
• [9]Gunar S, Rosa LG: Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: A systematic literature review. BioMed Central Nephrol 2011, 12(35):1-12.
• [10]Chan DC, Chen JH, Kuo HK, We CJ, Lu IS, Chiu LS, Wu SC: Drug-related problems (DRP) identified from geriatric medication safety review clinics. Arch Gerontol Geriatrics 2011, 54(1):168-174.
• [11]Somers A, Robays H, Vander SR, Van MG, Bogaert M, Petrovic M: Contribution of drug-related problems to hospital admission in the elderly. J Nutr Health Aging 2010, 14(6):477-482.
• [12]American Geriatrics Society: American geriatrics society updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012, 1-16. doi: 10.1111/j.1532-5415.2012.03923.x
• [13]Mafauzy M, Hussein Z, Chan SP: The status of diabetes control in Malaysia: Results of DiabCare 2008. Medical J Malay 2011, 66(3):175-181.
• [14]National Cholesterol Education Program: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285(19):2486-2497.
• [15]Jacobs MJ, Kleisli T, Pio JR, Malik S, L’Italien GJ, Chen RS, Wong ND: Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract 2005, 70:263-269.
• [16]Ministry of Health Malaysia: Clinical Practice Guidelines for: Management of Dyslipidemia. 4th edition. 2011. Retrieved 13 October 2011, from http://www.acadmed.org.my/index.cfm?&menuid=67 webcite
• [17]Reamer LB, Emily BM, Temple WS, Jane CA, Kit N: Pharmacy: Misleading, but manageable. Clin Interv Aging 2008, 3(2):383-389.
• [18]Ministry of Health Malaysia: Clinical Practice Guidelines for: Management of type 2 diabetes mellitus. 4th edition. 2009. Retrieved 11 October 2011, from http://www.acadmed.org.my/index.cfm?&menuid=67 webcite
• [19]Ministry of Health Malaysia: Clinical Practice Guidelines for: Management of Ischemic Stroke. 2006. Retrieved 23 October 2011, from http://www.acadmed.org.my/index.cfm?&menuid=67 webcite
• [20]Ministry of Health Malaysia: Clinical Practice Guidelines for: Management of Hypertension. 3rd edition. 2008. Retrieved 23 October 2011, from http://www.acadmed.org.my/view_file.cfm?fileid=312 webcite
• [21]Lacy CF, Armstrong LL, Goldman MP, Lance LL: Drug Information Handbook. Ohio: Lexi-Comp Inc; 2011.
• [22]British Medical Association & Royal Pharmaceutical Society: British National Formulary Edition 60. London: BMJ Group and Pharmaceutical Press; 2010.
• [23]Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD: Drug-related problems: Their structure and function. Ann Pharmacother 1990, 24:1093-1097.
• [24]Foppe VM: Drug-related problem: A cornerstone for pharmaceutical care. J Malta College of Pharmacy Practice 2005, 10:5-8.
• [25]Eichenberger PM, Lampert ML, Kahmann IV, van Mil JWF, Hersberger KE: Classification of drug-related problems with new prescriptions using a modified PCNE classification system. Pharmaceut Weekblad Sci Ed 2010, 32(3):362-372.
• [26]Eichenberger PM, Haschke M, Lampert ML, Hersberger KE: Drug-related problems in diabetes and transplant patients: an observational study with home visits. Int J Clin Pharm 2011, 33(5):815-823.
• [27]Granas AG, Berg C, Hjellvik V, Haukereid C, Kronstad A, Blix HS, Kilhovd B, Viktil KK, Horn AM: Evaluating categorization and clinical relevance of drug-related problems in medication reviews. Pharm World Sci 2010, 32:394-403.
• [28]Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H, Ohashi K: Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res 2005, 28(3):223-227.
• [29]Park CG, Lee H, Choi JW, Lee SJ, Kim SH, Lim HE: Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. Intl J Clin Pharmacol Therapeut 2010, 48(8):497-503.
• [30]Food and Drug Administration: FDA drug safety communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. 2011. Retrieved January 3, 2012, from http://www.fda.gov/drugs/drugsafety/ucm256581.htm webcite
• [31]Lorenzo AV, Ana MVC, Carlos O, Paloma E, Maria EF, Marcela Q: Pharmaceutical care program for dyslipidemic patients at three primary health care centers: Impacts and outcomes. Latin Am J Pharm 2009, 28(3):415-420.
• [32]Koh Y, Kutty FB, Li SC: Drug-related problems in hospitalized patients on polypharmacy: The influence of age and gender. J Therapeut Clin Risk Manag 2005, 1:39-48.
• [33]Babwah F, Baksh S, Blake L, Cupid-Thuesday J, Hosein I, Sookhai A, Poon-King C, Hutchinson : The role of gender in compliance and attendance at an outpatient clinic for type 2 diabetes mellitus in Trinidad. Revista Panam Salud Publica 2006, 19(2):79-84.
• [34]Carol V: Gender differences in determinants and consequences of health and illness. J Health Pop Nutrit 2007, 25(1):47-61.
• [35]Thomas MC, Macisaac RJ, Jerums G, Weekes A, Moran J, Shaw JE, Atkins RC: Non-albuminuric renal impairment in type 2 diabetic patients and in the general population (National evaluation of the frequency of renal impairment coexisting with NIDDM (Nefron) 11). Diabetes Care 2009, 32(8):1497-1502.
• [36]Hege SB, Kirsten KV, Tron AM, Aasmund R: Use of renal risk drugs in hospitalized patients with impaired renal function—an underestimated problem? Nephrol Dialysis Transplant 2006, 21:3164-3171.
• [37]Chan CM: Hyperlipidaemia in chronic kidney disease. Ann Acad Med Singapore 2005, 35:31-35.
• [38]Roger PA: Polypharmacy as a risk factor in the treatment of type 2 diabetes. Diabetes Spectrum 2006, 19(1):13-16.
• [39]Kirsten KV, Hege SB, Tron AM, Aasmund R: Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Brit J Clin Pharmacol. 2006, 63:2187-2195.
• [40]John CR, Kit FN, Hnin HA, Dennis WW: Role of triglyceride-rich lipoproteins in diabetic nephropathy. Nat Rev Nephrol 2010, 6:361-370.